SCHEMBL908503

SCHEMBL908503

CC1CN(c2ccccc2Cl)N=C1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 2/20 0.40
ALB P02768 4/20 0.37
NOTUM Q6P988 1/20 0.36
ADRB1 P08588 1/20 0.35
BRD4 O60885 1/20 0.35
PRKCZ Q05513 1/20 0.35
PTPN11 Q06124 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
MAOB P27338 1/20 0.33
DCPS Q96C86 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HTR5A P47898 2/20 0.33
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR7 P34969 1/20 0.33
HTR3A P46098 1/20 0.33
HTR6 P50406 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL908501 0.81 MEN1 (0.42) ROCK1NOTUMMAOBSMN1; SMN2ALDH1A1
SCHEMBL7719928 0.76 L3MBTL1 (0.40) ROCK1MAOBSMN1; SMN2ALDH1A1
SCHEMBL7721894 0.73 BRD4 (0.39) BRD4PRKCZMAOBALDH1A1
SCHEMBL908132 0.72 HSD11B1 (0.40) ROCK1SMN1; SMN2
SCHEMBL10846355 0.72 HTR3E (0.44) ROCK1PTPN11ALDH1A1HTR3A
SCHEMBL908243 0.72 DHFR (0.43) PTPN11SMN1; SMN2ALDH1A1HTR3A
SCHEMBL10846573 0.70 CNR2 (0.35) MAOBSMN1; SMN2ALDH1A1HTR1AHTR2A
SCHEMBL908400 0.68 ABL1 (0.54) ALBNOTUMADRB1ALDH1A1
SCHEMBL11063972 0.66 ALOX5 (0.42) PRKCZ
SCHEMBL30450769 0.65 ADRB1 (0.42) ALBADRB1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003862-A1 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases MERCK SHARP & DOHME LIMITED (GB) 2011-01-06 US claimed
EP-1987007-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LTD. (GB) 2008-11-05 EP claimed
WO-2007093829-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LIMITED (GB) 2007-08-23 WO claimed
US-20110003862-A1 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases MERCK SHARP & DOHME LIMITED (GB) 2011-01-06 US disclosed
EP-1987007-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LTD. (GB) 2008-11-05 EP disclosed
WO-2007093829-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LIMITED (GB) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003862-A1 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases DAO, DDO, MAOA ROCK1 3441/4885ALB 2056/4885NOTUM 3279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.